The law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of GenOn Energy, Inc. (“GenOn” or the “Company”) (NYSE: GEN), concerning the proposed acquisition of the Company by NRG Energy, Inc. (“NRG”) (NYSE: NRG). Under the terms of the transaction, GenOn shareholders would receive .1216 shares of NRG for every share they own. The current per-share value of the proposed consideration is approximately $2.28, and the total value of the transaction is approximately $1.7 billion.
GenOn has performed well recently, trading above the per-share offer price as recently as March 2012. At least one analyst has set a target price of $4.50 for the Company’s shares.
The investigation is focused on the potential unfairness of the consideration to GenOn shareholders, the process by which the Company’s Board of Directors considered the transaction, and potential conflicts of interests among GenOn’s Board members.
If you are interested in discussing your rights as a GenOn shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our web site at
. Attorney advertising. Prior results do not guarantee similar outcomes.